Introduction
In December 2005, Dr. J.R. Warren and Dr. B.J. Marshall were awarded the Nobel Prize for Physiology or Medicine [1] . At that time, although they received the award for their work on the culture and isolation of Helicobacter pylori and their recognition of the potent etiological relation of this organism to gastritis and peptic ulcer disease [2] , the possible relation of H. pylori to the development of gastric cancer had not yet been fully evaluated [1, 3] . However, in the period before their Nobel Prize award in 2005, outstanding fi ndings about the relationship between H. pylori and gastric and the list was limited to studies added to PubMed or published over the past 3 years (2006-2008) , to human studies, meta-analyses, practice guidelines, randomized controlled trials, clinical trials (phase I, II, III, IV), comparative studies, systematic reviews, and to studies including subjects older than 19 years. After compiling a list of the 108 studies included, 83 publications not directly involving the link between H. pylori and the development of gastric cancer were excluded. The remaining 25 studies were fi nally systematically reviewed.
Results of the literature review (Fig. 1)
Of the 25 clinical studies dealing with the relationship between H. pylori infection and the development of gastric cancer, 4 were randomized controlled trials (RCTs) [14] [15] [16] [17] , 1 was a meta-analysis [18] , 3 were cohort studies [19] [20] [21] , 9 were case-control studies [22] [23] [24] [25] [26] [27] [28] [29] [30] , and 8 examined gene polymorphisms related to the link between H. pylori and gastric cancer [26, [31] [32] [33] [34] [35] [36] [37] . Two European studies [38, 39] showed a relationship between dietary factors and H. pylori-associated gastric cancer development.
Randomized controlled trials (RCTs; Table 1)
You et al. [14] conducted an RCT to examine the effects of one-time H. pylori treatment and long-term intake of vitamin or garlic supplements in reducing the prevalence of advanced precancerous gastric lesions. In their study, most of the adults (age, 35-64 years) in 13 randomly selected villages underwent baseline endoscopies in 1994. Then, in 1995, 3365 eligible subjects were randomly assigned to one of three interventions or a placebo group: amoxicillin + omeprazole for 2 weeks in 1995; vitamin C, vitamin E, and selenium for 7.3 years; aged garlic extract and steam-distilled garlic oil for 7.3 years. The H. pylori eradication treatment resulted in a statistically signifi cant decrease in the combined prevalence of severe chronic atrophic gastritis, intestinal metaplasia (IM), dysplasia, and gastric cancer, as evaluated in 1999 (odds ration [OR], 0.77) and 2003 (OR 0.60), and had favorable effects on the average histopathologic severity and progression/regression of precancerous gastric lesions, as evaluated in 2003 [14] . Fewer subjects receiving H. pylori eradication therapy (1.7%) than the number receiving placebo (2.4%) developed gastric cancer (adjusted P = 0.14) [14] . No statistically signifi cant favorable effects were noted for garlic or vitamin supplementation [14] .
In a recent multicenter, open-label, RCT conducted in Japan on 544 patients with early gastric cancer [15] who were either newly diagnosed and scheduled for endoscopic treatment or were under post-resection follow up after endoscopic treatment, the patients were randomly assigned to receive H. pylori eradication therapy (n = 272) or no eradication (n = 272); at the time of the 3-year follow-up examination, metachronous gastric cancer was found to have developed in 9 patients in the eradication group and 24 patients in the control group [15] . In the full intention-to-treat (ITT) population, which included all patients irrespective of the length of follow up, the OR for the development of metachronous gastric cancer was 0.353 (95% confi dential interval [CI], 0.161-0.775; P = 0.009); in the modifi ed ITT population, which included patients with at least one post-randomization assessment of the tumor status and adjustment for loss to follow up, the hazard ratio (HR) for the development of metachronous gastric cancer was 0.339 (95% CI, 0.157-0.729; P = 0.003) [15] . Based on the results of this study [15] , the Japanese Society for Helicobacter Research (JSHR) revised their In a Korean study conducted on 1790 subjects [16] , gastric cancer was found to occur 10.9 times more frequently in the presence of IM than in its absence, suggesting that for effective prevention of gastric cancer [16] , H. pylori eradication therapy must be administered before the development of IM. IM lesions frequently show high expression levels of cyclooxygenase-2 (COX-2). According to a double-blind, randomized, placebo-controlled trial conducted by Leung et al. [40] , on subjects with confi rmed IM (n = 213) who were randomized to receive either rofecoxib or placebo, there was no evidence to suggest that treatment with rofecoxib for 2 years resulted in the regression of gastric IM [40] .
One study focused on the effi cacy of H. pylori eradication therapy for preventing the development of gastric hyperplastic polyps [17] . Forty-eight patients with hyperplastic gastric polyps infected with H. pylori were randomly assigned to an eradication group and a control group which received only the gastroprotective agent, teprenone [17] . While the polyps disappeared by 1-12 months after the treatment in 69% of the patients in the eradication group and H. pylori infection was eradicated in 86% of the patients, no change in the polyp or H. pylori status was observed in any of the patients in the control group by 12 months after the start of the study [17] .
The effi cacy of H. pylori eradication against the development of gastric cancer in the remnant stomach after gastrectomy has not been adequately assessed. A total of 138 patients with distal gastric cancer and H. pylori infection were randomized to receive H. pylori eradication therapy either preoperatively (preop) or postoperatively (postop) [41] . According to ITT analysis, the H. pylori eradication rate was 84.6% (95% CI, 73.5-92.4) in the preop group and 83.1% (95% CI, 71.7-91.2) in the postop group (P = 0.99), suggesting that the effect of H. pylori eradication was not signifi cantly different between the group administered the treatment postoperatively and the group administered the treatment preoperatively [41] .
To identify the molecular changes in the gastric mucosa following H. pylori eradication, Tsai et al. [42] used cDNA microarrays to analyze 54 gastric biopsies obtained in a randomized, placebo-controlled trial of H. pylori therapy. The results of the analysis revealed that, while in the eradication group, 30 genes could be identifi ed whose expression levels had changed signifi cantly from the baseline to 1 year after the treatment [42] , 55 genes whose expression levels had changed signifi cantly during the 1-year period (32 up-and 23 downregulated) could be identifi ed in the placebo group [42] . Five genes, involved in cell-to-cell adhesion and lining (TACSTD1 and MUC13), cell cycle/differentiation (S100A10), and lipid metabolism and transport (FABP1 and MTP) were downregulated in the eradication group but upregulated in the placebo group during the same 1-year period [42] .
Nonrandomized cohort studies (Table 2) Take et al. [19] reported a prospective cohort study conducted to determine the risk of development of gastric cancer in patients with peptic ulcer diseases; the severity of gastric atrophy was evaluated in this study. Among the 1131 patients followed up for up to 9.5 years, the risk of development of gastric cancer was decreased signifi cantly after H. pylori eradication. In addition, the development of gastric cancer was related to the severity of the baseline gastric mucosal atrophy. Analysis with a Cox's proportional hazards model identifi ed persistence of infection (HR, 3.35; 95% CI, 1.00-11.22) as signifi cant factors for the development of gastric cancer [19] . Takenaka et al. [20] conducted a retrospective cohort study to determine the cancer-preventive effect of H. pylori eradication (n = 1807) and reported that 6 of 1519 (0.39%) patients in whom H. pylori infection was eradicated and 5 of 288 (1.74%) subjects in whom the infection was persistent developed gastric cancer. Kaplan-Meier analysis also indicated a signifi cantly lower incidence of gastric cancer in the group with eradication of H. pylori infection than in the group with persistent infection (OR, 0.20; 95% CI, 0.061-0.66) [20] .
Case-control studies (Table 3) Plummer et al. [25] reported, based on the results of examination of gastric biopsy specimens obtained from 2145 participants, that the OR for gastric dysplasia was 15.5 in individuals infected with cagA-positive H.
pylori as compared with that in uninfected individuals and the OR was 0.90 in individuals infected with cagAnegative H. pylori as compared with that in uninfected individuals. Gwack et al. [22] conducted a nested casecontrol study of 100 patients with gastric cancer and 400 control subjects to examine the risk of gastric cancer in relation to the virulence factors of H. pylori in a Korean cohort. They showed that CagA seropositivity was signifi cantly associated with a higher risk of gastric cancer among H. pylori-infected subjects (OR, 3.57; 95% CI, 1.05-12.14) [22] .
H. pylori infection, atrophic gastritis, and dietary and lifestyle factors were evaluated as risk factors in a large nested case-control study in the European Prospective Investigation into Cancer and Nutrition trial carried out in nine countries (EPIC-EURGAST study), in 233 patients diagnosed as having gastric cancer after enrolment and 910 control subjects [24] . In a conditional logistic regression analysis conducted with adjustment for education, smoking, body weight, and total consumption of vegetables, fruits, and red and preserved meat, H. pylori seropositivity was associated with an increased risk of gastric cancer. The OR associated with severe chronic atrophic gastritis was 3.3 (95% CI, 2.2-5.2). According to site, the risk of noncardia gastric cancer associated with CagA seropositivity was increased further (OR, 6.5; 95% CI, 3.3-12.6); on the other hand, severe chronic atrophic gastritis was associated with a tenfold increase in the risk of gastric cancer of the cardia (OR, 11.0; 95% CI, 3.0-40.9). The causal relationship between infection with H. pylori CagA+ strains and gastric cancer in these European populations, even after dietary habits were taken into account, was limited to distal gastric cancer, while a low serum pepsinogen level was strongly associated with gastric cancer of the cardia, thus suggesting a divergent risk pattern for cancer at these two sites [24] .
Only a few papers have been published on H. pylori infection in gastric cancer patients younger than 40 [26] reported that the prevalence of H. pylori infection was higher in patients with gastric cancer than in patients with a normal endoscopic study or those with chronic gastritis, especially among subjects younger than 40 years old (OR, 13.7). Gastric cancer in patients younger than 40 years is closely associated with H. pylori infection.
Meta-analysis
Wang et al. [18] [18] .
Polymorphisms and H. pylori-associated gastric cancer (Table 4)
The interplay between bacterial factors and host gene polymorphisms may explain why gastric cancer occurs in only a small fraction of H. pylori-infected cohorts. Polymorphisms of the interleukin-1 beta gene (IL-1B) and interleukin-1 receptor antagonist gene (IL-1RN) have been shown to be associated with an increased risk of gastric atrophy and cancer, especially in H. pyloriinfected subjects. In an Omani Arab population, while IL-1RN polymorphism was found to be associated with an increased risk of gastric cancer, consistent with previous reports [43] , the IL-1B -31 polymorphism was not associated with increased gastric cancer risk [31] , sup- porting the notion of ethnic differences in the effect of IL-1B polymorphism on gastric carcinogenesis. According to a study by Zabaleta et al. [44] , the presence of the IL1B+3954T allele was a risk marker for multifocal atrophic gastritis in the population studied. Seno et al. [36] reported, based on a study of 207 single-nucleotide polymorphisms (SNPs), that polymorphisms of the IL-4 and IL-1RN genes were negatively associated with the risk of development of gastric cancer associated with H. pylori infection. On the other hand, the IL-8 -251 T/T genotype was associated with a signifi cantly increased risk of highfrequency microsatellite instability (MSI-H) gastric cancer compared with that of low-frequency MSI (MSI-L) or MSI-stable gastric cancers and noncancer controls [37] . The MPO -463G/G genotype, which is associated with increased myeloperoxidase (MPO) expression and antral IM, has been reported to be a risk factor for gastric cancer arising from the antrum [45] .
In relation to the association of gastric cancer with polymorphisms of genes responsible for Th1-cellmediated immune responses, Hou et al. [33] concluded, from a population-based study of 305 gastric cancer cases and 427 age-and sex-matched controls in Poland, that two Th1-related polymorphisms (TNFα -308 A > G and IFNγR2 Ex7-128 C > T) may be associated with an increased risk of gastric cancer.
Matrix metalloproteinase (MMP)-related SNPs, especially MMP-7(-181A > G) and TIMP-2(303C > T), might be helpful in identifying gastric cancer patients with a poor clinical outcome [34] . The TGFB1 T+869C gene polymorphism was shown to be involved in susceptibility to duodenal ulcer, but not in that to gastric cancer [32] . While 8-hydroxy-2′-deoxyguanosine (8-oxo-dG) levels in the gastric mucosa were increased in carriers of H. pylori, the levels were signifi cantly higher in a small subset of subjects having a homozygous variant allele of the 8-oxoguanosine-glycosylase 1 (OGG1) gene, which codes for the enzyme removing 8-oxo-dG from DNA [46] . The Pro12Ala PPARγ polymorphism has also been shown to be associated with the development of gastric cancer, and is a potential marker of genetic susceptibility to gastric cancer with H. pylori infection [35] .
E-Cadherin is an adhesion molecule thought to be involved in the development of gastric cancer. Germline mutations in the E-Cadherin gene (CDH1) have been identifi ed in hereditary diffuse gastric cancer, and a promoter polymorphism at position -160 C/A of CDH1 has been shown to infl uence the risk of gastric cancer in some studies [47, 48] . However, Jenab et al. [49] reported that none of the CDH1 polymorphisms or haplotypes analyzed were associated with gastric cancer risk.
Furthermore, according to a report by GarciaGonzalez et al. [50] , at least in some white populations examined in Spain, the contribution of the cytokine gene polymorphisms evaluated (IL-1B, IL-1RN, IL12p40, LTA, IL-10, IL-4 , and TGF-B1) to gastric cancer susceptibility may be less relevant than previously reported. Furthermore, although gastric cancer in patients younger than 40 years of age was shown to be closely associated with H. pylori infection, it was not associated with genetic polymorphism of P4502E1 (CYP2E1) [26] .
Dietary factors
Food factors seem to have a very important infl uence on the risk of development of gastric cancer. According to the EPIC-EURGAST study conducted by Gonzalez et al. [38] , while there seemed to be no evidence of any association between fresh fruit intake and gastric cancer risk, a negative association was possible between total vegetable (calibrated HR, 0.66; 95% CI, 0. , and they noted that this association between the risk of noncardia gastric cancer and total meat intake was especially pronounced in H. pylori-infected subjects (OR per 100-g/day increase, 5.32; 95% CI, 2.10 to 13.4) [39] .
Japanese guideline on the diagnosis and treatment of H. pylori infection
According to the previous guideline for physicians on the diagnosis and treatment of H. pylori infection in routine medical practice published by the Japanese Society for Helicobacter Research (JSHR) [51] , H. pylori eradication therapy was recommended in patients with low-grade duodenal ulcer. Although eradication therapy was also recommended for patients with lowgrade gastric mucosa-associated lymphoid tissue (MALT) lymphomas, it was suggested that this be undertaken only at specialist institutions. Furthermore, the signifi cance of H. pylori eradication therapy after endoscopic mucosal resection or gastrectomy for gastric cancer was still under evaluation, as was that in patients with hyperplastic polyps, chronic atrophic gastritis, or nonulcer dyspepsia. However, according to the recently updated guideline by the JSHR, H. pylori eradication is recommended at recommendation level A; i.e., based on strong scientifi c evidence, for all patients with H. pylori infection. A previous nonrandomized study [13] and recent open-label RCT [15] showed that H. pylori eradication after endoscopic resection for early gastric cancer could prevent the development of metachronous gastric cancer. As for the H. pylori eradication treatment, triple therapy, consisting of amoxicillin (AMX) and clarithromycin (CLR), along with a proton pump inhibitor (PPI), was offi cially authorized in the year 2000 as the fi rst-line regimen for H. pylori eradication in Japan. Then, in 2007, the combination of metronidazole (MNZ), AMX, and a PPI was approved as a second-line regimen. Although the H. pylori eradication rate following fi rstline treatment was around 90% in 2000 [52] , it has declined in recent years to less than 80%. Such eradication failure has been attributed mainly to the development of antibiotic resistance to CLR [53] (primary resistance rate, 9.1% [54] ; secondary resistance rate, 79.2% in Japan). Under such circumstances, the regimen for H. pylori eradication was switched to the secondline regimen consisting of AMX, MNZ, and a PPI [55, 56] . Even after treatment with the second-line regimen, a large-scale multicenter study in the Tokyo Metropolitan area showed that eradication failure was still observed in approximately 10% of patients [57] , suggesting an increasing demand for the development of third-line regimens.
In 2009, the JSHR has just established a board certifi cation system for doctors treating H. pylori infection; the JSHR aims to standardize the diagnostic and therapeutic medical skills required to eradicate this bacterium in Japan.
Summary
In summary, the association between H. pylori and the development of gastric cancer is now more clearly established than before. As announced by the JSHR recently, H. pylori eradication should be undertaken in all subjects who are infected, based on all the accumulated scientifi c evidence. For this purpose, standard effective H. pylori eradication protocols, including third-line regimens, should be urgently developed. Rokkas et al. [58] reported that, by adopting the fi rstand second-line regimens proposed by the Maastricht III consensus and a levofl oxacin (LEV)-based regimen as the third-line regimen, high cumulative eradication rates, of 89.6 % (ITT) and 98.1% (per protocol; PP), were achieved. Quinolones are one of the most suitable candidate categories for a third-line regimen [58, 59] , even though a high resistance rate to gatifl oxacin (43%) was reported in H. pylori isolated from patients with fi rst-and/or second-line eradication failure [53] . Recently, a new generation of quinolones (e.g., sitafl oxacin and garenoxacin) has been developed; in-vitro, these have been shown to overcome the resistance of H. pylori strains that have resistance-determining gyrA mutations, and these quinolones are expected to be tested clinically [60] . Another possible candidate component for a third-line eradication regimen is rifabutin [61] , which has very low resistance rates at present in Japan, although there remains the problem of crossresistance to rifampicin [62] . The effi cacy of the abovementioned candidate agents should be carefully evaluated in well-designed clinical trials.
In conclusion, we emphasize that, even after eradication of H. pylori has been achieved in patients with high-risk gastric mucosa (frequently seen in older subjects with severe gastric atrophy), endoscopic surveillance for gastric cancer should not be omitted in such high risk patients.
